Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 7/20 | 0.72 |
| ▸ | RAB9A | P51151 | 7/20 | 0.72 |
| ▸ | TP53 | P04637 | 5/20 | 0.72 |
| ▸ | MAPT | P10636 | 5/20 | 0.72 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.72 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.72 |
| ▸ | NFKB2 | Q00653 | 2/20 | 0.72 |
| ▸ | RELA | Q04206 | 2/20 | 0.72 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.55 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.55 |
| ▸ | MEN1 | O00255 | 1/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.55 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.54 |
| ▸ | F2RL3 | Q96RI0 | 9/20 | 0.52 |
| ▸ | CA12 | O43570 | 1/20 | 0.44 |
| ▸ | CA1 | P00915 | 1/20 | 0.44 |
| ▸ | CA2 | P00918 | 1/20 | 0.44 |
| ▸ | CA9 | Q16790 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19320617 | 0.85 | F2RL3 (0.76) | F2RL3 | |
| SCHEMBL18678469 | 0.76 | F2RL3 (0.73) | NPC1RAB9ATP53MAPTSMN1; SMN2 | |
| SCHEMBL13186820 | 0.72 | TP53 (0.74) | NPC1RAB9ATP53MAPTSMN1; SMN2 | |
| SCHEMBL23657842 | 0.72 | SMN1; SMN2 (1.00) | NPC1RAB9ATP53MAPTSMN1; SMN2 | |
| SCHEMBL10878341 | 0.71 | TP53 (1.00) | NPC1RAB9ATP53MAPTSMN1; SMN2 | |
| SCHEMBL5309504 | 0.71 | SMN1; SMN2 (0.72) | NPC1RAB9ATP53MAPTSMN1; SMN2 | |
| SCHEMBL16708205 | 0.71 | F2RL3 (0.80) | F2RL3 | |
| SCHEMBL18489825 | 0.70 | NPC1 (0.86) | NPC1RAB9AMAPT | |
| SCHEMBL16707966 | 0.70 | F2RL3 (0.74) | F2RL3 | |
| SCHEMBL16708157 | 0.70 | F2RL3 (0.77) | NPC1RAB9ATP53MAPTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9963466-B2 | Substituted 5-membered heterocyclic analogs as protease activated receptor 4 (PAR-4) antagonists | VANDERBILT UNIVERSITY (US) | 2018-05-08 | — | — | US | disclosed |
| US-20170253617-A1 | Substituted 5-Membered Heterocyclic Analogs as Protease Activated Receptor 4 (PAR-4) Antagonists | VANDERBILT UNIVERSITY | 2017-09-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170253617-A1 | Substituted 5-Membered Heterocyclic Analogs as Protease Activated Receptor 4 (PAR-4) Antagonists | F2RL3, F2R, F2RL1 | NPC1 2109/4885RAB9A 2218/4885TP53 1679/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.